Erratum to: Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort

Agnès Fournier · Sylvie Mesrine · Laure Dossus ·
Marie-Christine Boutron-Ruault · Françoise Clavel-Chapelon ·
Nathalie Chabbert-Buffet

Published online: 3 August 2014
© Springer Science+Business Media New York 2014

Erratum to: Breast Cancer Res Treat (2014)
145:535–543
DOI 10.1007/s10549-014-2934-6

In Table 1, percentages in the “MHT never users” column actually correspond to MHT past users, and percentages in the “MHT past users” column correspond to MHT never users. For instance, the percentage of women who

underwent a mammogram during the last follow-up period should be 75.0 % among MHT never users and 91.7 % among past users. The authors apologize for this error.

The online version of the original article can be found under doi:[10.1007/s10549-014-2934-6](https://doi.org/10.1007/s10549-014-2934-6).

A. Fournier (✉) · S. Mesrine · L. Dossus ·
M.-C. Boutron-Ruault · F. Clavel-Chapelon
Inserm, Center for Research in Epidemiology and Population
Health, U1018, Nutrition, Hormones and Women’s Health
Team, 94807 Villejuif, France
e-mail: agnes.fournier@gustaveroussy.fr

A. Fournier · S. Mesrine · L. Dossus · M.-C. Boutron-Ruault ·
F. Clavel-Chapelon
Univ Paris-Sud, UMRS 1018, 94807 Villejuif, France

A. Fournier · S. Mesrine · L. Dossus · M.-C. Boutron-Ruault ·
F. Clavel-Chapelon
Institut Gustave Roussy, 94805 Villejuif, France

N. Chabbert-Buffet
Department of Obstetrics-Gynecology and Reproductive
Medicine, APHP Hôpital Tenon, Univ. Pierre Et Marie Curie
Paris 06, Paris, France